
To assess the cardiovascular safety, zzso and efficacy of high doses of zzso for the treatment of zzso and vomiting in patients undergoing highly zzso zzso 

Patients with zzso confirmed zzso disease were given an intravenous infusion of zzso 160 zzso over 30 zzso starting 15 zzso after highly zzso zzso Patients underwent cardiac monitoring for 24 h following the zzso zzso zzso blood pressure and zzso zzso II and zzso zzso were taken, and routine clinical chemistry and zzso tests zzso Blood samples for zzso analysis were taken before the zzso infusion, and at intervals zzso zzso events were zzso using a symptom zzso zzso zzso rating scales were used to evaluate patient zzso vomiting and zzso 

Ten patients zzso females and two zzso average age zzso zzso completed the trial and were included in the safety and efficacy zzso No clinically relevant changes in zzso pulse rate, blood pressure or laboratory parameters were zzso Furthermore, in the 7 days following dosing there were no serious adverse events leading to withdrawal from the zzso A complete response (no zzso zzso or, at most, mild zzso was experienced by five zzso Six patients had no, or mild, zzso and an additional two patients zzso on a maximum of two zzso Additional zzso rescue medication was given to three patients during the zzso trial zzso Despite considerable zzso zzso zzso and zzso parameters were zzso greater than values reported for lower doses of zzso 

zzso administered at four times the upper recommended dose demonstrated good efficacy and zzso with no clinically important cardiac zzso 

